A Study Evaluating the Efficacy and Safety of Mosunetuzumab in Combination With Lenalidomide in Comparison to Rituximab in Combination With Lenalidomide With a US Extension of Mosunetuzumab in Combination With Lenalidomide in Participants With Follicular Lymphoma (NCT04712097)
Phase III Randomized, Open-Label, Multicenter Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination With Lenalidomide in Comparison to Rituximab in Combination With Lenalidomide With a Non-Randomized Single Arm US Extension of Mosunetuzumab in Combination With Lenalidomide in Patients With Follicular Lymphoma After at Least One Line of Systemic Therapy
🩺 Plain-English Summary (8th-Grade Level)
This study will evaluate the efficacy and safety of mosunetuzumab in combination with lenalidomide (M + Len) compared to rituximab in combination with lenalidomide (R + Len) in participants with relapsed or refractory (R/R) follicular lymphoma (FL) who have received at least one line of prior systemic therapy.
Who can join: Review the eligibility criteria below.
Location: City of Hope Comprehensive Cancer Center — Duarte, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (112 Sites)
Showing the first 25 of 112 sites.
- City of Hope Comprehensive Cancer Center — Duarte, California
- Winship Cancer Institute — Atlanta, Georgia
- Fort Wayne Medical Oncology and Hematology, Inc — Fort Wayne, Indiana
- Investigative Clinical Research of Indiana, LLC — Noblesville, Indiana
- Johns Hopkins Uni — Baltimore, Maryland
- University of Michigan Health System — Ann Arbor, Michigan
- Cancer & Hematology Center of West Michigan — Grand Rapids, Michigan
- Washington University — St Louis, Missouri
- NYU Long Island Hospital — Mineola, New York
- NYU Langone Ambulatory Care Center — New York, New York
- Montefiore Medical Center - Montefiore Medical Park — The Bronx, New York
- Montefiore Medical Center — The Bronx, New York
- Duke University Medical Center — Durham, North Carolina
- Wake Forest Univ Health Svcs — Winston-Salem, North Carolina
- Baylor University Medical Center — Dallas, Texas
- MD Anderson Cancer Center — Houston, Texas
- Kadlec Clinic Hematology and Oncology — Kennewick, Washington
- Calvary Mater Newcastle — Waratah, New South Wales
- Princess Alexandra Hospital Woolloongabba — Woolloongabba, Queensland
- Royal Adelaide Hospital — Adelaide, South Australia
- Geelong Hospital — Geelong, Victoria
- ICTR Curitiba — Curitiba, Paraná
- Hospital das Clinicas - UFRGS — Porto Alegre, Rio Grande do Sul
- Hospital Mae de Deus — Porto Alegre, Rio Grande do Sul
- Hospital Alemao Oswaldo Cruz — São Paulo, São Paulo
📞 Contact the Study Coordinator
Phone: (800) 826-4673
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Relapsed or Refractory Follicular Lymphoma
- huCART19-IL18-eDHFR Cells in Relapsed/Refractory Follicular Lymphoma — Philadelphia, Pennsylvania
Explore by condition: All Relapsed or Refractory Follicular Lymphoma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.